Following Jeremy Hunt’s 2023 budget delivered earlier this month, in which he paved the way for faster access to new drugs and revealed R&D tax credits for life sciences companies, Bloomberg looked at the many challenges still facing the UK’s life sciences sector. Despite the success of the Oxford Covid-19 vaccine, the UK is still […]
6TH OCTOBER 2022 | LONDON
Amolyt is developing therapeutic peptides for rare endocrine and related diseases, including AZP-3601 (eneboparatide) for hypoparathyroidism Proceeds will fund the Phase 3 programme for hypoparathyroidism, as well as its growing endocrine pipeline Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, has announced it has invested in a €130 million (approx. $138 million) […]
COPENHAGEN, DENMARK — Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use. The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep’s standardised liquid chromatography platform. The new […]
BioInnovation Institute (BII), an international enterprise foundation with a non-profit objective incubating and accelerating world-class life science research, announces today that it has accepted a new project into its Bio Studio program. Based on recent breakthroughs in Artificial Intelligence (AI) and protein design, the project is creating a new class of therapeutic proteins to modulate […]
